Protalix BioTherapeutics Inc. (DE) Common Stock (PLX)

About PLX

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Website

protalix.com/

Fundamentals

Market cap

$196.59M

P/E (trailing)

12.40

P/E (forward)

—

EPS (trailing)

$0.18

Dividend yield

—

Beta

-0.09

Avg. volume

—

Protalix BioTherapeutics Inc. (DE) Common Stock Competitors

Chosen by industry and closest market cap.

• PLX

  Protalix BioTherapeutics Inc. (DE) Common Stock

  $2.54

  ▼ 2.68%
  Market cap $196.59MP/E 12.40
  $1.52$3.19
• IVVD

  Invivyd Inc. Common Stock

  $0.9628

  ▲ 6.98%
  Market cap $194.15MP/E —
  $0.5277$3.07
• VYGR

  Voyager Therapeutics Inc. Common Stock

  $3.54

  ▲ 2.17%
  Market cap $189.12MP/E —
  $2.94$5.55
• ARMP

  Armata Pharmaceuticals Inc. Common Stock

  $5.24

  ▼ 3.50%
  Market cap $172.54MP/E —
  $2.4$16.34
• LENZ

  LENZ Therapeutics Inc. Common Stock

  $5.12

  ▲ 6.34%
  Market cap $163.67MP/E —
  $4.54$50.4
• MOLN

  Molecular Partners AG American Depositary Shares

  $4.5

  ▼ 3.27%
  Market cap $163.47MP/E —
  $2.66$3.96
• TARA

  Protara Therapeutics Inc. Common Stock

  $3.82

  ▼ 4.26%
  Market cap $230.44MP/E —
  $3.02$7.82

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/12/2026
• Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate
  Benzinga · 8/12/2026

Institutional Ownership

March 31, 2026

Total shares held

16.52M

Total value held

$35.51M

Institutional holders

97